期刊文献+

一种新型抗HCV药物筛选细胞模型建立的研究 被引量:3

Study on Establish of a Cell Model for Screening Anti-HCV Drugs
暂未订购
导出
摘要 目的构建HCV5’NCR调控外分泌性碱性磷酸酶(SEAP)基因表达的细胞模型。方法用PCR技术扩增HCV5’NCR片段,定向克隆至表达质粒pSEAP2-Control的SEAP基因上游,构建HCV5’NCR调控SEAP表达的重组质粒pdNCRSEAP。用脂质体基因转染技术,将pdNCRSEAP转染至肝细胞株Huh-7。用化学发光法检测SEAP的表达,并观察不同浓度反义寡聚核苷酸(ASODN)对SEAP表达的影响。结果重组质粒pdNCRSEAP表达的发光强度为pSEAP2-Control的78%,5μmol和10μmolASODN对pdNCRSEAP发光强度的抑制率分别为31.2%和48.6%,而对pSEAP2-Control的SEAP表达无显著抑制作用(P>0.05)。结论重组质粒pdNCRSEAP的SEAP表达受HCV5’NCR调控,为以HCV5’NCR为靶位点的药物筛选建立了检测方便的细胞模型。 Objective To establish a cell model of secreted alkaline phosphatase (SEAP) controlled by HCV 5'noncoding region. Methods The fragment of HCV 5'noncodingregion (5'NCR) was amplified by polymerase chain reaction (PCR), and was immediately cloned the upstreamof the SEAP gene of SEAP2-Control,an SEAP eukaryotic expression plasmid. With the liposome transfection technique, the resulting recombinant plasmid pdNCRSEAP was transfected into hepatocytes Hnh-7, and the SEAP activity of cell culture media was monitored quantitatively by the chemiluminescent method. The regulatory effect of the HCV 5'NCR on the SEAP expression was measured by the treatment of transfected cells with antisense oligodeoxynucleotide (ASODN) at 5μmol and 10 μmol, respectively. Results The light emission intensity of pdNCRSEAP expression was 78% that of pSEAP2-Control. The inhibition rates of pNCRSEAP luminescence intensity affected by ASODN of 5 μmol and 10μtmol were 31.2% and 48.6%, respectively, while ASODN had no significant effect on the pSEAP2-Control expression. Conclusion The SEAP expression of pdNCRSEAP is controlled by HCV 5'NCR. The cell model of drug evaluation targeted at HCV 5'NCR is successfully established and can be analyzed conveniently.
出处 《深圳中西医结合杂志》 2005年第4期216-219,共4页 Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
基金 深圳市科技计划项目(JH 200507120860A)
关键词 抗HCV 细胞模型 药物筛选 基因转染技术 反义寡聚核苷酸 SEAP 重组质粒 发光强度 PCR技术 Hepatitis C virus Secreted alkaline phos-phatase (SEAP), A cell model
  • 相关文献

参考文献7

  • 1李勇年,王勤环,斯崇文,于敏,刘芳.丙型肝炎病毒基因调控细胞模型的建立及其意义[J].中华医学杂志,1997,77(8):609-610. 被引量:6
  • 2Bukh J, Purcell RH, Miller RH. Sequence analysis of the 5' noncoding region of hepatitis C virus (J). Proc Natl Acad Sci USA, 1998, 89(11):4942-4946.
  • 3Wang C, Sarnow P, Siddiqui A. Translation of human hepatitisC virus RNA in cultured cells is mediated by an internal ribosome2binding mechanism (J). J Virol, 1999,67(6):3338-3344.
  • 4Alt M, Renz R, Hofschneider PH, et al. Specific inhibition of hepatitis C viral gene expression by antisense hosphorothioate oligo dexynucleotides (J). Hepatology, 2002, 22(3):709-717.
  • 5Manns ME McHutchison J G, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa22b plus rib-avirin for initial treatment of chronic hepatitis C: arandomized trial (J). Lancet, 2003, 358(9286):958-965.
  • 6Rijinbrand R, Bredenbeek PJ, Haasnoot PC, et al. The influence of downstream protein2coding sequence on internal ribosome entry on hepatitis C virus and other flavivirus RNAs (J). RNA, 2003, 7(4):585-597.
  • 7王小红,王升启,朱宝珍.反义寡核苷酸对HCV5′NCR基因调控功能的特异性抑制作用[J].中华微生物学和免疫学杂志,2000,20(5):436-437. 被引量:3

二级参考文献3

共引文献6

同被引文献61

  • 1邹坚,陈鸿珊.抗HCV药物研究进展[J].中国药学杂志,2004,39(6):403-408. 被引量:4
  • 2刘水平,谭德明,杨永峰,侯周华.丙型肝炎病毒5'端非编码区和NS3蛋白酶共调控外分泌性碱性磷酸酶表达细胞模型的建立及意义[J].中华肝脏病杂志,2004,12(9):552-554. 被引量:2
  • 3Ying-SongWu YuFeng Wen-QiDong Yan-MingZhang MingLi.A vaccinia replication system for producing recombinant hepatitis C virus[J].World Journal of Gastroenterology,2004,10(18):2670-2674. 被引量:12
  • 4刘艳,张贺秋,凌世淦,祁自柏.丙型肝炎病毒(HCV)培养模型的研究进展[J].细胞与分子免疫学杂志,2005,21(B03):125-127. 被引量:5
  • 5Shepherd J, Jones J, Hartwell D, et al. Interferon alpha (pegylted and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess, 2007,11 ( 11 ), 1-205.
  • 6Manns M P, Wedemeyer H, Cornberg M. Treating viral hepatitis C : efieacy, side effects, and complications. Gut, 2006,55 ( 9 ) : 1350-1359.
  • 7Manns M P, Foster G R, Rockstroh .JK. et al. The way forward in HCV treatment-finding the fight path. Nat Rev Drug Discov, 2007,6(12) :991-1000.
  • 8Soler M, McHutchison J G,Kwoh T J, et al. Virological effects of ISIS 14805, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRESin chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment. Antivir Ther,2004,9 (6) :953-968.
  • 9De Francesco R, Carfi A. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymcrase of the hepatitis C virus. Adv Drug Deliv Rev,2007,59f121:1242-1262.
  • 10McHutchison J, Everson G, Gordon S, et al. PROVE. 1 : results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment · -naive subjects with hepatitis. J Hepatoll, 2008,48 Suppl 2:4.

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部